[
  {
    "question": "30 Y male with Coital headache (very severe) coming to ER, the headache has improved but only mild improvement; next step: (not complet)",
    "option_a": "(CT scan) is correct because immediate non",
    "option_b": "(LP) is only appropriate if CT is negative despite ongoing high clinical suspicion. Option c (Reassurance) is inappropriate prior to excluding serious pathology.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Coital headache, especially when described as very severe and sudden, is a red-flag presentation that may signal subarachnoid hemorrhage or other intracranial pathology. In such scenarios, the first step is to perform neuroimaging to exclude life\u2010threatening causes before attributing the headache to a primary benign condition. Coital headaches can be primary (benign exertional) or secondary to underlying vascular events, such as a ruptured aneurysm causing subarachnoid hemorrhage. In SAH, bleeding into the subarachnoid space triggers a sudden rise in intracranial pressure and meningeal irritation. A non-contrast CT scan detects blood with high sensitivity, particularly within the first 24 hours of hemorrhage. A 30-year-old male presenting with a sudden and severe headache during or after sexual intercourse fits the profile of a thunderclap headache. Although his symptoms have improved slightly, the residual headache raises concern for incomplete resolution of a potentially catastrophic event like SAH. The most common differentials include primary coital headache, subarachnoid hemorrhage, and rarely other vascular anomalies. A non-contrast CT scan is the first diagnostic step. If the CT scan is negative but clinical suspicion remains high, particularly beyond the imaging window, a lumbar puncture can be considered to look for xanthochromia. First-line management includes immediate non-contrast CT imaging to rule out hemorrhage. If CT findings are negative and suspicion persists, proceed with a lumbar puncture. For pregnant patients, CT (with appropriate shielding and dose minimization) may still be used as the risk of missing a hemorrhage outweighs potential radiation risks, though MRI is an alternative in specific settings. For lactating women, similar considerations apply with counseling on minimal radiation exposure. Option a (CT scan) is correct because immediate non-contrast CT is the initial, most sensitive test for detecting acute hemorrhage. Option b (LP) is only appropriate if CT is negative despite ongoing high clinical suspicion. Option c (Reassurance) is inappropriate prior to excluding serious pathology. 1. Thunderclap headaches during coitus require prompt imaging to rule out hemorrhage. 2. Non-contrast CT is highly sensitive in the first 24 hours of a subarachnoid hemorrhage. Recent guidelines and studies, including those from the American Heart Association, emphasize the importance of early non-contrast CT imaging in evaluating acute severe headaches to rapidly identify or exclude life-threatening conditions such as SAH.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of TN and asked about the diagnosis (hint in the Q was that it is triggered by touching his face) he also has lacrimation.",
    "option_a": "TN",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia (TN) is characterized by brief, paroxysmal, lancinating facial pain triggered by activities such as touching the face. The presence of an identified trigger (touching the face) strongly points toward TN. TN typically results from demyelination of the trigeminal nerve, most often due to neurovascular compression (commonly by the superior cerebellar artery). This demyelination leads to nerve hyperexcitability and spontaneous ectopic discharges, resulting in the classic episodic pain. Patients with TN often describe sudden, electric shock-like pain in the trigeminal nerve distribution. The pain is highly reproducible by triggering maneuvers, such as light touch, and may occasionally be associated with lacrimation due to reflex autonomic activation. Diagnosis is primarily clinical after excluding secondary causes. An MRI can be utilized to assess for neurovascular compression or other structural lesions. Differential diagnoses include dental problems, cluster headache, and atypical facial pain. Management primarily revolves around medical therapy with anticonvulsants, with carbamazepine being the first-line treatment. In pregnant or lactating women, careful risk-benefit analysis is required; alternative therapies or dose adjustments may be considered along with close monitoring and supplementation (e.g., folic acid with carbamazepine use). Option A (TN) is correct, as the clinical presentation\u2014including trigger by facial touch and lacrimation\u2014is classic for trigeminal neuralgia. Other options would likely represent alternative diagnoses and are not supported by the clinical clues. 1. TN is often triggered by even slight tactile stimulation. 2. MRI is useful in excluding secondary causes and confirming neurovascular compression in TN. Current research stresses the role of neurovascular compression in the pathogenesis of TN, and guidelines recommend early neuroimaging to exclude secondary causes. The clinical diagnostic criteria remain largely unchanged, emphasizing the paroxysmal and triggerable nature of the pain.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of TN (hint in the Q was that it is triggered by touching his face) he also has lacrimation and asked about the management",
    "option_a": "carbamazepine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The management of trigeminal neuralgia focuses on reducing ectopic nerve discharges responsible for the characteristic paroxysmal pain. Carbamazepine has long been considered the first-line treatment for TN. Carbamazepine helps stabilize hyperexcitable neural membranes by blocking voltage-gated sodium channels, thereby reducing the abnormal neuronal firing that characterizes TN pain. Patients with TN typically experience sharp, lancinating facial pain that can be triggered by minimal stimulation, such as light touch. The efficacy of carbamazepine in reducing these paroxysmal episodes is well documented. Diagnosis of TN is based on clinical features, and neuroimaging (MRI) is often done to rule out secondary causes such as multiple sclerosis or space-occupying lesions. Differential diagnoses include dental pain and atypical facial pain. First-line management for TN is medical treatment with carbamazepine. If carbamazepine is ineffective or not tolerated, options such as oxcarbazepine can be considered. In pregnant women, carbamazepine poses teratogenic risks and requires careful consideration with folic acid supplementation and monitoring; alternative therapies and multidisciplinary management might be needed. In lactating women, the drug passes into breast milk, warranting similar vigilance. Option A (carbamazepine) is correct as it is the universally accepted first-line agent for TN. Other options, while they may be considered in refractory cases, are not recommended as first-line therapy. 1. Carbamazepine is the cornerstone of TN management, often successfully reducing pain attacks. 2. Start with a low dose and titrate slowly to minimize side effects. Recent guidelines and multiple randomized trials support carbamazepine as the first-line treatment for trigeminal neuralgia. Ongoing studies continue to assess its efficacy relative to newer agents in specific populations, including pregnant and lactating women, where risk mitigation strategies are essential.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Male with occipital headache radiating to the frontal area, on exam he has tenderness over the occipital protuberance and headache worse with head movement What's the Rx:",
    "option_a": "(Occipital nerve block) is correct because it provides prompt pain relief and confirms the diagnosis of occipital neuralgia. Option b (Carbamazepine) is more appropriate for trigeminal neuralgia and has not shown a similar efficacy profile for occipital neuralgia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Headache",
    "explanation": "Occipital neuralgia is characterized by paroxysmal, shooting pain in the distribution of the occipital nerves, often with tenderness over the occipital protuberance. The pain may radiate to the frontal region. Occipital neuralgia results from irritation, entrapment, or compression of the greater and/or lesser occipital nerves. This irritation may be due to trauma, tight muscles, or cervical spine pathology, leading to neuropathic pain. Patients typically present with localized pain at the back of the head that can radiate forward, along with point tenderness over the occipital region. Exacerbation with neck movement helps distinguish it from other headache syndromes like tension-type headaches. The diagnosis is mainly clinical. Differential diagnoses include tension-type headache, cervical spondylosis, and migraine. An occipital nerve block is both diagnostic and therapeutic; if the block alleviates the pain, it confirms the diagnosis of occipital neuralgia. First-line treatment is an occipital nerve block with local anesthetic (and sometimes corticosteroids if inflammation is suspected). If pain persists, second-line treatments include oral neuropathic agents like gabapentin or topiramate, along with physical therapy. In pregnant patients, nerve blocks are generally safe with proper local anesthetic selection, and non-pharmacologic measures are preferred to minimize systemic drug exposure. In lactating women, similar principles apply with careful choice of medications that do not adversely affect the infant. Option a (Occipital nerve block) is correct because it provides prompt pain relief and confirms the diagnosis of occipital neuralgia. Option b (Carbamazepine) is more appropriate for trigeminal neuralgia and has not shown a similar efficacy profile for occipital neuralgia. 1. An occipital nerve block can serve both a diagnostic and therapeutic role in managing occipital neuralgia. 2. Occipital neuralgia typically presents with focal tenderness, which helps differentiate it from other headache causes. Latest guidelines and expert consensus in headache management endorse occipital nerve blocks as the first-line treatment for occipital neuralgia. Recent clinical studies have demonstrated their efficacy in reducing pain intensity and improving quality of life, reinforcing their role in early management.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with headache and tearing etc\u2026 duration <5 min occurs 20-30/day, dx?",
    "option_a": "SUNCT",
    "option_b": "Hemicrania Continua",
    "option_c": "Chronic PH",
    "option_d": "does not contribute to the differential. Therefore, Option A is the correct answer.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is a rare primary headache disorder classified under the trigeminal autonomic cephalalgias. It is characterized by very brief, high-frequency headache attacks accompanied by ipsilateral cranial autonomic symptoms, most notably lacrimation and conjunctival injection. The pathophysiology of SUNCT is thought to involve abnormal activation of the posterior hypothalamus and dysfunction in the trigeminal-autonomic reflex. Neuroimaging studies have demonstrated brainstem and hypothalamic involvement, suggesting that dysregulation in these regions may precipitate the attacks. Patients with SUNCT typically present with unilateral orbital, periorbital, or temporal pain. The attacks are extremely brief (lasting seconds to less than 5 minutes) and may occur 20-30 times a day or even more. Accompanying symptoms include lacrimation, redness of the eye, and sometimes nasal congestion or rhinorrhea. Diagnosis is primarily clinical, relying on the International Classification of Headache Disorders (ICHD) criteria. It requires a detailed headache history that emphasizes the duration, frequency, and associated autonomic features. Neuroimaging, especially MRI of the brain, is essential to exclude secondary causes. Differential diagnosis includes chronic paroxysmal hemicrania, cluster headache, trigeminal neuralgia, and hemicrania continua. Current management of SUNCT is challenging due to the condition\u2019s refractory nature. Options include the use of anti-epileptics such as lamotrigine and topiramate, with lamotrigine often considered first-line. Intravenous lidocaine can be used in refractory cases. In pregnancy and lactation, treatment decisions must weigh the potential teratogenic risk and safety profile of medications. Lamotrigine is relatively favorable compared to other antiepileptics, but the risk-benefit analysis should be individualized, and consultation with maternal-fetal medicine may be warranted. Option A, SUNCT, is the most appropriate diagnosis given the brief duration (<5 minutes) and high frequency (20-30/day) of attacks, along with the presence of tearing. Option B (Hemicrania Continua) is characterized by continuous unilateral headache with exacerbations rather than discrete, brief attacks. Option C (Chronic Paroxysmal Hemicrania) typically has attacks that last 2-30 minutes and shows absolute responsiveness to indomethacin. The blank Option D does not contribute to the differential. Therefore, Option A is the correct answer. Key to diagnosing SUNCT is recognizing the extremely short duration of attacks coupled with autonomic features like conjunctival injection and tearing, which differentiate it from other TACs. A negative indomethacin trial helps exclude paroxysmal hemicrania. Neuroimaging is required to rule out secondary causes such as posterior fossa lesions. Evidence for the treatment of SUNCT remains limited, primarily based on case series and expert opinion. Recent literature supports the use of lamotrigine as a first-line agent, with other treatments including topiramate and trial of intravenous lidocaine in refractory cases. Ongoing research continues to explore the neurobiological underpinnings and optimal therapeutic strategies for SUNCT, especially considering the challenges of managing this condition in special populations such as pregnant and lactating women.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came for 3rd opinion, she was diagnosed as Cluster HA and Another trigeminal Autonomic Cephalgia, how to distinguish between them ? Duration",
    "option_a": "Duration",
    "option_b": "Response to treatment",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral head pain with ipsilateral cranial autonomic features (e.g., lacrimation, conjunctival injection, nasal congestion). The most common TAC is cluster headache, but paroxysmal hemicrania (PH) and SUNCT/SUNA also belong to this category. Differentiation between cluster headache and PH is critical, as each requires a distinct treatment approach. While the exact mechanisms are not fully understood, cluster headache is associated with hypothalamic activation leading to trigeminal autonomic activation. Paroxysmal hemicrania, on the other hand, may involve sensitization of pain pathways and prostaglandin-mediated mechanisms, which is a basis for its dramatic response to indomethacin. This different underlying pharmacologic responsiveness hints at divergent pathophysiologic mechanisms between these disorders. Cluster headache typically presents with severe, unilateral periorbital pain lasting 15 to 180 minutes with a clustering of attacks, whereas paroxysmal hemicrania involves shorter attacks (2 to 30 minutes) that occur more frequently. However, a more distinguishing clinical feature is the absolute responsiveness of PH to indomethacin, which is not seen in cluster headache. The diagnosis relies on a detailed clinical history focusing on attack duration, frequency, and associated symptoms. In cases where there is diagnostic uncertainty between cluster headache and other TACs like PH, a therapeutic trial of indomethacin is recommended. A complete, absolute response to indomethacin supports a diagnosis of PH. Differential diagnoses include other TACs (like SUNCT/SUNA) and secondary headache causes, making a comprehensive history and sometimes imaging essential. The management of these headaches differs significantly. Cluster headache is typically managed with acute therapies such as high-flow oxygen and sumatriptan, and the use of verapamil for prophylaxis. In contrast, paroxysmal hemicrania is managed with indomethacin, which is considered diagnostic if the response is absolute. In pregnant patients, oxygen and some triptans (under close supervision) may be preferred for cluster headache, whereas the use of indomethacin is limited in pregnancy, especially in the third trimester, due to potential fetal risks. Alternatives and careful risk\u2013benefit analyses must be considered during pregnancy and lactation. Option A (Duration) is a useful criterion because the typical attack duration in cluster headache (15\u2013180 minutes) is different from that in paroxysmal hemicrania (2\u201330 minutes). However, duration alone can sometimes be ambiguous. Option B (Response to treatment), specifically the absolute response to indomethacin, is considered the hallmark in differentiating paroxysmal hemicrania from cluster headache. Therefore, the response to treatment is the most reliable and definitive distinguishing feature. A complete and marked response to indomethacin should prompt the diagnosis of paroxysmal hemicrania rather than cluster headache. When faced with overlapping clinical features of TACs, always evaluate both the temporal profile of attacks and therapeutic responses. Recent guidelines and reviews, including updates from ICHD, reinforce that an indomethacin trial is essential in patients suspected of having paroxysmal hemicrania. The dramatic response to indomethacin, as opposed to the typically poor response in cluster headache, remains the cornerstone of diagnostic differentiation. Studies continue to support the differentiation based on treatment response rather than duration alone, due to variability in attack duration.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a migraine patient came to you doing well, his headaches are controlled, asked you to prescribe him pregabalin as he\u2019s taking it occasionally on weekends to make him relax?",
    "option_a": "Refer to psychiatry",
    "option_b": "Refill for 3 months",
    "option_c": "give him gabapentin instead",
    "option_d": "Refuse his request and discharge him from OPD",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This question tests the clinician\u2019s ability to recognize the potential for prescription misuse in a patient with a stable chronic condition. The key concept is that prescribing medications like pregabalin for purposes other than their indicated uses\u2014especially when the patient is already well-managed (migraine in this case)\u2014may suggest underlying psychological issues or substance misuse. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system. This decreases the release of excitatory neurotransmitters such as glutamate and substance P, which is helpful in neuropathic pain and generalized anxiety under indicated circumstances. However, its off-label or non-indicated use for relaxation can lead to dependence and misuse, given its potential for euphoria and sedation. In clinical practice, a patient with well-controlled migraine asking for pregabalin solely to 'relax' raises concern. Such a request may reflect an underlying psychiatric condition or misuse behavior. Addressing this behavior early is important to prevent potential abuse, dependency, or diversion of medications with known abuse potential. The key differentials include evaluating for an underlying anxiety disorder, substance use disorder, or behavioral pattern suggesting misuse of prescription medication. A detailed history, validated screening tools for substance abuse, and psychiatric evaluation are recommended when a patient requests a medication in a non-standard, non-indicated manner. The decision to refer the patient to psychiatry (Option A) is appropriate. It aligns with current clinical guidelines that recommend addressing suspected prescription misuse or underlying psychiatric concerns through a multidisciplinary approach. When managing such cases, especially in women of childbearing age or those who are pregnant/lactating, it is essential to note that pregabalin is generally used with caution (often categorized as Category C) due to potential fetal effects. Alternative therapies with proven safety profiles should be considered if psychiatric management leads to pharmacotherapy. Option A (Refer to psychiatry) is correct because it encourages further evaluation of the patient\u2019s request in the context of potential misuse or an underlying psychiatric condition. Option B (Refill for 3 months) inappropriately rewards the request without addressing the concern. Option C (Give him gabapentin instead) merely substitutes one similar medication for another without mitigating the risk of misuse. Option D (Refuse his request and discharge him from OPD) is overly punitive and eliminates opportunities for further assessment and intervention. \u2022 When a patient with a stable chronic condition requests a medication outside of its indicated use, consider the possibility of underlying psychological issues or substance misuse. \n\u2022 A thorough psychosocial history and screening for medication abuse is crucial. \n\u2022 Always consider the specific risks of centrally acting medications, particularly regarding their use in pregnant or lactating patients. Recent studies and guidelines emphasize caution when prescribing medications with abuse potential. They recommend that neurologists and primary care physicians should screen for psychiatric comorbidities in patients who request medications like pregabalin for off-label uses. The multidisciplinary approach, including psychiatric referral, is essential in managing these complex cases and preventing future misuse or dependency.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Female young Migraine patient, DM, she\u2019s a university student best rx needs preventive medication?",
    "option_a": "Amitriptyline (Can cause sedation)",
    "option_b": "Propranolol",
    "option_c": "Topamax",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis is tailored to individual patients by taking into account both the migraine characteristics and comorbid conditions. In young female patients with diabetes mellitus, it is important to choose agents that do not worsen glycemic control or lead to unwanted weight gain. Migraines are believed to involve neurovascular dysregulation with changes in neuronal excitability and alterations in pain pathways. Preventive agents work by modulating neuronal excitability, reducing cortical spreading depression, and stabilizing these pathways. Topiramate, as an antiepileptic drug, reduces excitability by blocking voltage-dependent sodium channels and enhancing GABA activity, thereby preventing migraine episodes. In a young diabetic woman, using medications that can lead to weight gain or adverse metabolic effects (like some beta blockers or tricyclic antidepressants) is less desirable. Topiramate is known for its potential to promote modest weight loss, which may be beneficial in patients with diabetes. However, it also has potential cognitive side effects which must be weighed against its benefits, especially for a university student. Migraine is primarily a clinical diagnosis, based on a detailed history (including headache frequency, duration, associated symptoms) and by excluding secondary headache causes. Differential diagnoses include tension-type headache and cluster headache. In this setting, the patient\u2019s comorbid diabetes also guides the choice of prophylactic agent. Current guidelines recommend several first-line migraine preventive medications including beta blockers (e.g., propranolol), tricyclic antidepressants (e.g., amitriptyline), and antiepileptic drugs (e.g., topiramate and, in some cases, valproate which is avoided in women of childbearing potential). For this patient, topiramate is a particularly attractive option due to its potential benefit in weight reduction; however, when prescribing it to a woman of childbearing age, counseling on teratogenic risk and appropriate contraception is essential. Amitriptyline (Option A) can cause sedation and weight gain, which is counterproductive in a diabetic. Propranolol (Option B) has the risk of masking hypoglycemia, a significant concern in diabetic patients. Topamax (Option C) offers benefits for migraine prevention and may aid with weight loss, making it the most suitable choice here. 1. Beta blockers can mask signs of hypoglycemia and may not be ideal in diabetic patients. 2. Topiramate not only helps reduce migraine frequency but also may promote weight loss. 3. Always assess the risk\u2013benefit profile in women of child-bearing potential, considering teratogenicity risks. Recent updates from the American Headache Society and clinical trials support the individualized selection of preventive therapy in migraine. Topiramate has been validated as an effective prophylactic agent, particularly in patients where weight reduction is a therapeutic goal, though clinicians remain cautious regarding its cognitive side effects.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Migraine patient's MRI brain showed hyperintense small lesions? What to do?",
    "option_a": "Start treatment",
    "option_b": "reassurance",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "It is well documented that patients with migraine may have incidental neuroimaging findings, such as white matter hyperintensities. Recognizing these as benign findings reduces unnecessary interventions. The hyperintense small lesions found on MRI in migraine patients are believed to represent benign microvascular changes or transient oligemic events rather than active demyelination or ischemic injury. They are common and generally do not reflect an underlying progressive pathology. Most migraine patients who undergo MRI end up with these incidental findings without corresponding neurological deficits. This is particularly true when the clinical scenario is otherwise typical for migraine without signs of neurological compromise. Differentials for white matter lesions include multiple sclerosis, small vessel ischemic disease, and other demyelinating processes. Careful clinical correlation (lack of progressive neurological deficits, normal neurologic exam aside from migraine features) helps differentiate benign migraine-related lesions from these other conditions. There is no indication for additional therapeutic intervention for these incidental findings. The current consensus is to provide reassurance and continue standard migraine management. No specific treatment aimed at the lesions themselves is warranted. Option A (Start treatment) is unnecessary because the lesions do not indicate a progressive disease. Option B (Reassurance) is the correct approach given the benign nature of the findings. Options C and D are not provided or applicable. 1. White matter hyperintensities are common incidental findings in migraine patients. 2. Their presence should not prompt aggressive workup in the absence of additional neurological abnormalities. 3. Correlate radiologic findings with clinical presentation to avoid overtreatment. Recent neuroimaging research confirms that these hyperintensities are typically benign and non-progressive in migraine patients. Updated guidelines stress the importance of correlating clinical findings with imaging to avoid unnecessary treatments or anxiety.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Pregnant 10 wk of gestation, severe migraine what to give",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Migraine management in pregnancy, especially during the first trimester, requires caution due to the potential teratogenicity and adverse fetal effects of many medications. Non-pharmacologic management is preferred when possible. Many migraine medications have mechanisms of action that can interfere with fetal development in the critical period of organogenesis. This is particularly relevant in the first trimester when the risk for teratogenicity is highest. In a 10\u2010week gestation patient with severe migraine, the potential risks to the fetus from pharmacological agents (such as NSAIDs, triptans, ergot derivatives, and prophylactic antiepileptics) often outweigh the benefits if the migraine is not life-threatening or vision-threatening. When evaluating migraine in pregnancy, it is crucial to differentiate a primary migraine disorder from other headache syndromes (such as tension-type headache or secondary causes). Detailed history and assessment are required, and imaging studies are used judiciously. The current guidelines suggest using non-pharmacologic management as first-line therapy for migraine during the first trimester. If pharmacotherapy is absolutely necessary, acetaminophen is preferred as it is the safest option. NSAIDs are avoided due to miscarriage risk, and triptans have limited safety data in early pregnancy. Ergot derivatives and prophylactic medications like valproate or topiramate are contraindicated. Therefore, the best approach is to avoid specific migraine medications unless absolutely necessary. Acetaminophen, while considered safe, might be insufficient for severe migraine. NSAIDs, triptans, and ergot derivatives have known risks in the first trimester. The analysis supports that no specific abortive or prophylactic pharmacologic treatment should be given (i.e., 'None'), which corresponds to the marked answer (Option D). 1. First trimester migraine management prioritizes fetal safety over aggressive pharmacotherapy. 2. Acetaminophen remains the first-line drug if pharmacologic treatment is required. 3. Non-pharmacologic strategies (e.g., dark room rest, hydration, stress reduction) are key components of management. Recent guidelines and research emphasize conservative management of migraine in early pregnancy. Updated consensus statements recommend minimizing medication use during organogenesis while reserving pharmacologic treatment for refractory cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Female with headache, occasional blurring when she lean forward, papilledema only no visual filed defects or VA decrease,, suggestive of IIH what tx",
    "option_a": "Oral prednisone",
    "option_b": "IV methylprednisone",
    "option_c": "Weight loss",
    "option_d": "Optic nerve fenestration",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Idiopathic Intracranial Hypertension (IIH) primarily affects overweight women and is characterized by elevated intracranial pressure with no obvious cause. The cornerstone of management is non-invasive lifestyle modification, particularly weight loss. IIH is due to increased intracranial pressure arising from impaired cerebrospinal fluid (CSF) absorption and possibly increased venous sinus pressure. Obesity is a significant risk factor that exerts a physiological effect on CSF dynamics. Patients with IIH typically present with headache, transient visual obscurations (such as brief blurring when bending over), and papilledema, yet they may maintain normal visual acuity and visual fields in early stages. The absence of significant visual field defects or visual acuity loss confirms a less aggressive course that can initially be managed conservatively. The diagnosis of IIH is supported by findings on a neurological exam (papilledema) alongside normal neuroimaging (to exclude other causes) and confirmed by lumbar puncture with elevated opening pressure. Differentials include cerebral venous sinus thrombosis, optic neuritis, and intracranial mass lesions. The first-line management of IIH is weight loss combined with lifestyle modifications. Pharmacologic therapy with acetazolamide is typically initiated when weight loss alone is insufficient to control symptoms or if there are impending visual threats. Steroids are generally avoided except in acute, severe scenarios, and optic nerve fenestration is reserved for rapid or progressive visual loss. In pregnancy and lactation, weight loss is advocated with nutritional counseling, though pharmacotherapy must be used judiciously. Oral prednisone (Option A) and IV methylprednisone (Option B) are not first-line due to their side-effect profiles and are avoided unless in acute severe scenarios. Optic nerve fenestration (Option D) is a surgical option reserved for refractory cases with imminent visual loss. Weight loss (Option C) represents the most appropriate initial management step in IIH, making it the correct answer. 1. Weight loss is the cornerstone in managing IIH and can significantly reduce intracranial pressure. 2. Acetazolamide is added when weight loss alone does not suffice. 3. Early diagnosis and management are crucial to prevent permanent visual impairment. Recent studies and guidelines from neurology societies affirm the central role of weight loss in the management of IIH. Current research also supports the use of acetazolamide as a complementary treatment, with surgical interventions reserved for severe, vision-threatening cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Female pregnant with status migrainosus in 3rd trimester",
    "option_a": "Methylprednisolone",
    "option_b": "Intranasal DHE",
    "option_c": "Valproic acid",
    "option_d": "SC sumatriptan",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Status migrainosus is defined as a severe migraine attack lasting more than 72 hours and refractory to usual abortive therapies. In a pregnant patient, especially in the 3rd trimester, treatment selection must balance maternal benefit with fetal safety. Migraines involve neuronal hyperexcitability and dysregulation of brainstem and peripheral vascular pathways. Triptans, like sumatriptan, act as selective 5-HT1B/1D receptor agonists, causing cranial vasoconstriction and modulation of pain pathways, thereby aborting the migraine attack. In pregnancy, many conventional migraine treatments are restricted: NSAIDs are often avoided in the 3rd trimester due to risks of premature ductus arteriosus closure, while many prophylactic agents are contraindicated. Sumatriptan is the most studied triptan in pregnancy and has been used effectively for acute migraine attacks. For a pregnant woman presenting with prolonged and severe migraine, it is essential to rule out secondary causes (e.g., eclampsia, cerebral venous sinus thrombosis). However, if the clinical picture fits migraine, abortive therapy is indicated. Differential diagnoses include medication overuse headache and other intracranial pathologies. Treatment in pregnancy focuses on using medications with the best safety profiles. Among the options provided: \u2022 Intranasal DHE is contraindicated due to its ergot properties that can induce uterine contractions. \u2022 Valproic acid is highly teratogenic. \u2022 Methylprednisolone, a corticosteroid, is sometimes used as a bridging therapy in refractory cases but is not typically a first-line acute abortive treatment. \u2022 SC Sumatriptan, with its rapid relief and extensive safety data in the second and third trimesters, is generally preferred. For patients in the 3rd trimester, sumatriptan\u2019s risk profile is acceptable given the benefits in aborting a debilitating status migrainosus attack. Pregnancy and lactation guidelines support its use when necessary. Option A (Methylprednisolone): While corticosteroids have been used to reduce migraine attack duration and prevent recurrence, they are not the primary abortive treatment, especially when a more targeted therapy is available. Option B (Intranasal DHE): Ergot derivatives are contraindicated in pregnancy due to their vasoconstrictive effects on uterine vessels. Option C (Valproic Acid): Is contraindicated in pregnancy because of its high teratogenic risk. Option D (SC Sumatriptan): Has demonstrated efficacy for acute migraine relief and a favorable safety profile in pregnancy, making it the optimal choice for abortive therapy in this patient. \u2022 Sumatriptan is among the most studied triptans in pregnancy and is generally considered safe for use during the second and third trimesters. \u2022 In status migrainosus, rapid abortive therapy is key; while steroids can be used as adjunct therapy, they do not offer the immediate relief that sumatriptan does. \u2022 Avoid ergot derivatives and teratogenic agents such as valproic acid during pregnancy. Recent observational studies and post-marketing surveillance have shown that sumatriptan does not confer a significant increase in fetal malformations when used during pregnancy, particularly in the later trimesters. Current guidelines from obstetric and headache societies support the cautious use of sumatriptan for acute severe migraines in pregnancy when indicated.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about HC asking about tx",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua (HC) is a primary headache disorder characterized by a persistent, strictly unilateral headache with superimposed exacerbations and accompanying autonomic features. A definitive feature of HC is its dramatic, complete response to indomethacin, which not only treats the condition but also serves as a diagnostic criterion. The exact mechanisms underlying HC remain incompletely understood, but the syndrome is believed to involve dysregulation in the trigeminal-autonomic pathways and central pain modulation. The robust response to indomethacin implies that prostaglandin-mediated inflammation or cyclooxygenase pathways may play a significant role in its pathophysiology. Patients with HC typically present with a continuous, unilateral headache that may worsen periodically, along with ipsilateral autonomic symptoms such as lacrimation, rhinorrhea, or ptosis. The persistence and unilateral nature of the pain, combined with a near-absolute response to indomethacin, help differentiate HC from other primary headache disorders like cluster headache or paroxysmal hemicrania. The diagnosis of HC is primarily clinical. The differential diagnosis includes other trigeminal autonomic cephalalgias (e.g., cluster headache, paroxysmal hemicrania) and even migraine. However, a therapeutic trial of indomethacin is both diagnostic and therapeutic\u2014if the patient experiences complete remission of symptoms, HC is confirmed. Indomethacin is the treatment of choice for HC because of its unique, absolute efficacy in this condition. When managing patients, it is essential to consider pregnancy and lactation. In pregnant women\u2014especially during the third trimester\u2014NSAIDs like indomethacin are generally contraindicated due to the risk of premature closure of the fetal ductus arteriosus. Alternatives or careful dosing with close monitoring might be necessary. In lactating women, caution is also advised due to potential adverse effects on the infant, and alternative management strategies should be considered if possible. The provided option A (Indomethacin) is the correct answer based on its well-established therapeutic and diagnostic role in HC. While the other options are not listed, they would likely include other analgesics or NSAIDs lacking the definitive response required to confirm the diagnosis of HC. A near-complete resolution of headache symptoms following an indomethacin trial is pathognomonic for hemicrania continua. Always assess for contraindications to NSAIDs, particularly in women who are pregnant or lactating, and modify treatment accordingly. Recent clinical guidelines and studies continue to endorse indomethacin as the first-line treatment for HC, confirming its unique efficacy. Contemporary research emphasizes cautious use in special populations such as pregnant or breastfeeding women, where alternative therapies or modified treatment protocols may be necessary.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "23 yo Female type 1 DM last year of colleague with indication for prophylaxis of her migraine what to give",
    "option_a": "Topiramate",
    "option_b": "Valproic acid, no mention of pregnancy",
    "option_c": "Propranolol",
    "option_d": "Amitriptyline",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis in women of childbearing age requires choosing agents with a favorable safety profile in pregnancy. Although several medications (including topiramate, valproic acid, propranolol, and amitriptyline) are effective for migraine prophylaxis, antiepileptics such as topiramate and valproic acid have significant teratogenic risks. In a 23\u2010year\u2010old woman\u2014with potential future pregnancy and type 1 diabetes\u2014safe alternatives like beta blockers or tricyclic antidepressants are preferred. Migraines involve complex neurological mechanisms including cortical spreading depression, neurogenic inflammation, and activation of the trigeminovascular system. Propranolol likely improves migraine symptoms by stabilizing vascular tone, reducing excitability, and interrupting the cycle of migraine initiation via beta-adrenergic blockade. Patients with frequent or debilitating migraines benefit from prophylactic treatment. However, in women of reproductive age, the teratogenic potential of certain antiepileptics (topiramate and valproate) mandates caution. Additionally, in type 1 diabetic patients, use of beta blockers requires careful monitoring because they can mask the adrenergic warning signs of hypoglycemia. The diagnosis of migraine is clinical, relying on a detailed history and characteristic headache features (unilateral location, pulsating quality, associated nausea, photophobia/phonophobia). Differential diagnoses include tension-type headaches and other secondary headache disorders. The patient\u2019s overall profile (young, female, diabetic) steers the choice of prophylactic therapy. According to current guidelines, first-line migraine prophylaxis in women of childbearing age favors agents with minimal teratogenic risk. Beta blockers (such as propranolol) and tricyclic antidepressants (like amitriptyline) are preferred. While beta blockers are effective, caution is warranted in type 1 diabetic patients because of the risk of masking hypoglycemic symptoms. Regardless, topiramate and valproate are generally avoided due to their well-documented teratogenicity. In pregnancy and lactation, propranolol is used if the benefits outweigh potential risks, with close monitoring; patients are counseled regarding effective contraception until it is safe to conceive. Option A (Topiramate) is effective for migraine prophylaxis in general but is not ideal in young women due to its association with congenital malformations (e.g., cleft lip/palate). Option B (Valproic Acid) carries a high teratogenic risk and is contraindicated in women of childbearing potential. Option C (Propranolol) is a first\u2010line prophylactic agent for migraine, and with appropriate diabetic monitoring (given the risk of masking hypoglycemia), it is the safest choice among the alternatives. Option D (Amitriptyline) is a reasonable alternative but is not as commonly used as first-line as propranolol in a patient whose profile favors avoiding teratogenic antiepileptics. \u2022 In women of childbearing potential, always avoid migraine prophylactic agents with high teratogenic risks (e.g., valproic acid and topiramate) unless no alternatives exist. \n\u2022 In type 1 diabetic patients, beta blockers like propranolol should be used with caution due to the potential blunting of hypoglycemic warning signs. \n\u2022 A thorough discussion regarding contraception and pregnancy planning is essential when initiating prophylactic therapy in this patient population. Recent guidelines from the American Headache Society and other expert bodies support the use of beta blockers (such as propranolol) as first-line agents in migraine prophylaxis when there are no contraindications. Furthermore, extensive data highlights the teratogenic risks associated with topiramate and valproate, leading to their avoidance in women with potential pregnancy. In patients with type 1 diabetes, while beta blockers require vigilance regarding hypoglycemia, their overall benefit-risk profile in migraine prophylaxis makes propranolol the preferred option.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Another scenario of SUNCT (no triggers) what is the tx",
    "option_a": "Lamotrigine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is a rare primary headache disorder marked by brief, severe unilateral head pain accompanied by cranial autonomic symptoms. It is classified among the trigeminal autonomic cephalalgias (TACs). Although the precise mechanism remains not fully elucidated, SUNCT is thought to involve dysfunction within the trigeminal nociceptive pathways along with hypothalamic activation. This dysfunction leads to a cascade of neural and vascular events responsible for the abrupt pain and autonomic features. Patients with SUNCT typically experience attacks lasting from 5 to 240 seconds, often with extremely high pain intensity. The lack of reproducible triggers in some cases does not rule out SUNCT. Differential diagnoses include cluster headache, paroxysmal hemicrania, and trigeminal neuralgia. Careful history and adherence to ICHD-3 criteria are crucial. Diagnosis is primarily clinical, based on the characteristic short-lasting, recurrent headache attacks with ipsilateral autonomic signs. Neuroimaging is usually indicated to exclude secondary causes. Differential diagnosis should consider other TACs and secondary headache disorders. Lamotrigine is recognized as a first-line prophylactic treatment for SUNCT, particularly effective in reducing the frequency and severity of attacks. Management strategies are primarily prophylactic given the difficulty in aborting attacks once initiated. In pregnant or lactating patients, clinicians must consider the risk\u2013benefit ratio. Lamotrigine is sometimes used during pregnancy (with careful monitoring and dose adjustments due to altered pharmacokinetics in pregnancy) and lactation, though the clinician should be vigilant regarding potential risks and consult current guidelines for antiepileptic use in these populations. Given the limited options provided and acknowledging that lamotrigine is well supported by clinical evidence and expert opinion as an effective prophylactic agent in SUNCT, option A (Lamotrigine) is confirmed as the correct answer. \u2022 SUNCT is a medically challenging headache disorder largely due to its rapid, recurrent nature.\n\u2022 A gradual titration of lamotrigine is recommended to minimize adverse effects while achieving optimal control of attacks.\n\u2022 It is important to exclude secondary causes and consider the full differential, especially in atypical presentations.\n\u2022 In populations such as pregnant and lactating women, careful assessment and interdisciplinary management are necessary. Recent literature, including case series and observational studies, supports the use of lamotrigine in reducing the frequency and severity of SUNCT attacks. Although controlled trials are limited due to the rarity of the condition, the accumulated clinical experience and expert guidelines consistently endorse lamotrigine as the preferred prophylactic agent.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Best anti-emetic medication for migraine",
    "option_a": "(Domperidone) is less effective centrally due to poor blood",
    "option_b": "(Ondansetron) targets 5",
    "option_c": "(Metoclopramide) works both centrally and peripherally via dopamine antagonism and prokinetic effects, making it the best option. Option D is not provided.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Headache",
    "explanation": "Migraines are often accompanied by nausea and vomiting. The use of anti-emetics not only addresses these symptoms but also aids in improving the absorption of oral migraine medications. Metoclopramide, a dopamine D2 receptor antagonist, is particularly effective because it acts both centrally and peripherally, making it ideal for migraine-associated nausea. Migraine involves complex neurological processes including activation of central pathways and neurotransmitter dysregulation (notably dopamine and serotonin). Metoclopramide blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) as well as in the gastrointestinal tract, which helps modulate the nausea and vomiting that are mediated by both central and peripheral mechanisms. Its prokinetic effects further promote quicker gastric emptying, indirectly enhancing the efficacy of concurrently administered oral migraine treatments. Patients with migraine frequently experience nausea, which can impede the absorption of migraine-specific medications like triptans. By controlling nausea, metoclopramide not only improves patient comfort but also ensures that orally administered migraine therapies are delivered effectively. Its action on both the CTZ and gastrointestinal tract makes it uniquely suited for this purpose. In the evaluation of migraine-related nausea, clinicians use patient history along with the clinical presentation. Differential diagnoses might include gastroenteritis, cyclic vomiting syndrome, or medication-induced nausea. A careful evaluation ruling out other causes of nausea and correlating timing with migraine onset is essential. According to current guidelines, metoclopramide is recommended as a first-line anti-emetic in the treatment of migraine-associated nausea. Its use as an adjunct has been validated in numerous clinical studies. In pregnancy and lactation, the use of metoclopramide should be weighed against potential risks; it is generally considered when benefits outweigh risks, although caution is advised. Alternatives (like ondansetron) are generally less effective in migraine-induced nausea because the role of dopaminergic pathways outweighs that of 5-HT3 receptors in this setting. Option A (Domperidone) is less effective centrally due to poor blood-brain barrier penetration. Option B (Ondansetron) targets 5-HT3 receptors which are more relevant to chemotherapy-induced nausea rather than migraine. Option C (Metoclopramide) works both centrally and peripherally via dopamine antagonism and prokinetic effects, making it the best option. Option D is not provided. 1) Metoclopramide\u2019s dual action makes it valuable in migraine management by addressing both nausea and medication absorption. 2) Use of anti-emetics can significantly improve patient outcomes by ensuring that migraine-specific medications are effectively absorbed. Current migraine management guidelines continue to support metoclopramide as a first-line anti-emetic in migraine. Recent studies emphasize its benefit in improving gastrointestinal motility and enhancing the efficacy of oral abortive therapies, and its role remains well-established in clinical practice.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Commonest presentation in Arnold Chiari malformation?",
    "option_a": "Hydrocephalus",
    "option_b": "Seizure",
    "option_c": "Ataxia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Arnold-Chiari malformation, typically referring to Chiari type II malformation, is a congenital anomaly characterized by the herniation of hindbrain structures through the foramen magnum. It is commonly associated with neural tube defects such as myelomeningocele and hydrocephalus. In Arnold-Chiari malformation (Chiari II), there is downward displacement of the cerebellum, brainstem, and fourth ventricle, which often leads to obstruction of cerebrospinal fluid (CSF) pathways. This obstruction is responsible for the development of hydrocephalus in many patients. The resultant increased intracranial pressure contributes to the typical clinical signs seen in affected individuals. The clinical presentation of Chiari II often includes signs of hydrocephalus (such as increased head circumference in infants, headaches, and vomiting) in addition to cerebellar dysfunction, including ataxia. Among the provided options, hydrocephalus is the most common and significant presentation due to its high incidence in Chiari II malformation. Magnetic resonance imaging (MRI) of the brain and cervical spine is the diagnostic modality of choice for detecting structural abnormalities of the hindbrain and CSF flow disruptions. Differential diagnoses include other causes of pediatric hydrocephalus such as aqueductal stenosis, intraventricular hemorrhage, or congenital malformations. Management of Arnold-Chiari malformation focuses on relieving CSF obstruction and associated hydrocephalus, often through neurosurgical interventions such as ventriculoperitoneal shunting and posterior fossa decompression. In pregnant patients, neurosurgical management should be carefully coordinated with obstetrical care, and radiological investigations should minimize fetal exposure. Option A (Hydrocephalus) is correct because it is the most common and significant complication of Arnold-Chiari malformation. Option B (Seizure) is not a characteristic presentation of Chiari II malformation, and Option C (Ataxia), while possible due to cerebellar involvement, is less common compared to hydrocephalus in the context of Chiari II. 1) Hydrocephalus occurs in a significant majority of children with Chiari II malformation. 2) Early recognition and management of CSF flow obstruction are crucial in improving patient outcomes. Recent guidelines and studies underscore the importance of early neurosurgical intervention in patients with Chiari II malformation presenting with hydrocephalus, which remains the hallmark of this condition. Advances in imaging and surgical techniques continue to improve prognostic outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Male came with 40 times unilateral pain on forehead lasting for 1 min with conjunctival injection and tearing no trigger what tx.",
    "option_a": "Lamotrigine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The presentation of unilateral, brief, highly recurrent headache attacks accompanied by autonomic symptoms (such as conjunctival injection and tearing) is most consistent with a trigeminal autonomic cephalalgia. In particular, the description is typical of SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing). SUNCT is thought to involve abnormal activation and dysfunction of the trigeminal nerve along with hypothalamic involvement, leading to rapid and frequent headache episodes and ipsilateral cranial autonomic symptoms. The underlying mechanisms are not fully elucidated but likely involve both peripheral and central nervous system components. Patients with SUNCT experience very short headache attacks (ranging from seconds to a few minutes), which may occur many times a day. The attacks are accompanied by prominent ipsilateral autonomic features such as conjunctival injection and lacrimation. This presentation distinguishes SUNCT from other headache syndromes like cluster headache, which typically last longer. Differentiation is based primarily on attack duration, frequency, and associated autonomic signs. Differential diagnoses include cluster headache (typically lasts 15-180 minutes), paroxysmal hemicrania (shorter duration but with a clear response to indomethacin), and trigeminal neuralgia (typically presents with sharp, electric shock-like pain without prominent autonomic features). MRI and neuroimaging may be used to exclude secondary causes. Lamotrigine is considered first-line therapy for SUNCT due to its ability to stabilize neuronal membranes and decrease the frequency of headache attacks. Second-line treatments may include topiramate or gabapentin. In acute settings, intravenous agents such as lidocaine have been used. During pregnancy and lactation, the use of lamotrigine requires careful consideration; while lamotrigine is one of the safer antiepileptic drugs in pregnancy, appropriate dose adjustments and surveillance of serum levels are necessary due to altered pharmacokinetics. Option A (Lamotrigine) is correct as evidence supports its efficacy in reducing the frequency and severity of SUNCT attacks. Other options (not provided) such as indomethacin are more characteristic of paroxysmal hemicrania, and treatments for cluster headache (e.g., oxygen or triptans) are less effective for SUNCT. 1) SUNCT is characterized by extremely brief, yet very frequent, unilateral headache episodes with prominent lacrimation and conjunctival injection. 2) Lamotrigine is the treatment of choice and should be titrated slowly due to the risk of skin reactions. Recent research and clinical guidelines reaffirm lamotrigine as the first-line treatment for SUNCT. Studies highlight its efficacy in reducing attack frequency, and ongoing trials continue to explore additional therapeutic options for refractory cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "30 years old patient with previous diagnosis of migraine presents with daily headache for the past 3 months. Unlike her migraine, these headaches are not has nausea/vomiting/photophobia. She says headaches are constant so she must take ibuprofen and many other analgesics with no much improvements. What is the likely diagnosis?",
    "option_a": "Typical migraine",
    "option_b": "Medication overuse",
    "option_c": "cluster",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Medication overuse headache (MOH) is a secondary headache disorder where frequent use of analgesic medications leads to a chronic daily headache pattern. Patients with a history of episodic migraine may develop a transformation in headache pattern when they overuse pain-relieving medications. The underlying mechanism of MOH is thought to involve central sensitization, where repeated exposure to analgesics disrupts normal pain modulation pathways. This results in an increased headache frequency and a change in headache characteristics over time. The loss of typical migrainous features like nausea and photophobia is common as the pattern shifts from episodic to chronic. The patient\u2019s history of episodic migraines combined with the evolution to a daily, constant headache pattern without the typical migrainous features strongly suggests medication overuse headache. The patient\u2019s increased use of ibuprofen and other analgesics is a key factor in this transformation, leading to a refractory headache that does not respond well to further analgesics. Diagnosis is primarily clinical, based on the history of frequent use of analgesic medications and the evolution of headache pattern. Differential diagnoses include chronic migraine, tension-type headache, and secondary headaches from other causes. A thorough medication history is critical, and diagnostic criteria as per ICHD-3 can be used to confirm MOH. The primary management of MOH involves complete withdrawal of the overused medications, along with patient education and sometimes the initiation of preventive therapies for the underlying primary headache disorder. Bridging therapy may be needed during the withdrawal phase. In pregnant and lactating patients, careful management is essential; non-pharmacological strategies and safe preventive options should be considered to minimize risks to the fetus or infant. Option A (Typical Migraine) is incorrect because the patient\u2019s current headache lacks the classic symptoms of migraine (e.g., nausea, vomiting, photophobia) and has a chronic, unremitting pattern. Option B (Medication Overuse) is correct given the patient\u2019s heavy analgesic use and the transformation of headache pattern. Option C (Cluster) is not consistent with the history or presentation as cluster headaches have a different clinical profile and autonomic features. 1) A history of medication overuse is a common and modifiable cause of chronic daily headache in patients with migraine. 2) Successful treatment of MOH typically begins with the cessation of the offending agent, which can lead to significant improvement in headache frequency and intensity over time. Recent guidelines support the diagnosis and management of MOH through detoxification of the overused medication, followed by the initiation of preventive therapies. Emerging research also emphasizes the need for early identification and intervention to prevent chronification of migraine symptoms.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of acute onset daily headache which is constant and not related to any triggering factors or any other symptoms, with duration more than 3 months?",
    "option_a": "Tension headache",
    "option_b": "Meningitis",
    "option_c": "New daily persistent headache",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "New daily persistent headache (NDPH) is a primary headache disorder characterized by an abrupt onset of a continuous daily headache that persists without remission for more than 3 months. The key is its sudden onset and unremitting nature from the very first day. The underlying mechanism of NDPH remains not fully understood. It may involve a persistent activation of nociceptive pathways after an inciting event (sometimes viral or stressful) that leads to a continuous pain state. Although neuroinflammatory mediators and central sensitization have been implicated, definitive biomarkers have not been established. Patients typically describe an acute onset of a constant headache with little variability in daily severity and without identifiable triggers or associated features like those seen in migraines. This contrasts with other primary headaches such as tension-type headache, which may have a more gradual onset and fluctuating intensity. Diagnosis is clinical and one of exclusion. Differential diagnoses include chronic tension-type headache (which often has a more bilateral, pressing quality), chronic migraine (with possible auras or associated symptoms), and secondary causes such as meningitis (which would typically include fever and neck stiffness). Detailed history, neuroimaging when indicated, and assessment of associated symptoms help differentiate NDPH from other headache syndromes. There is no universally accepted treatment. Management often involves symptomatic relief with analgesics, adjuvant therapies (such as amitriptyline or other neuromodulatory agents), and sometimes non-pharmacologic interventions. In patients who are pregnant or lactating, careful analgesic selection is required; acetaminophen is generally considered safe, while many other options must be used with caution or avoided. Option A (Tension headache) is typically characterized by a band\u2010like pressure that builds up gradually, not an abrupt continuous headache. Option B (Meningitis) would usually present with fever, neck stiffness, and possibly altered mental status, features absent in this scenario. Option C (New daily persistent headache) precisely fits the description given in the question. 1. NDPH is defined by its sudden onset and continuous headache that persists for over three months. 2. It is a diagnosis of exclusion and often refractory to standard treatments. 3. Always rule out secondary causes in new-onset daily headaches. Recent literature emphasizes the difficulty in treating NDPH; research is ongoing regarding the role of anti-inflammatory and neuromodulatory agents. There is also increasing focus on non-pharmacologic management strategies. No specific breakthrough treatment has yet been established as first-line.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]